BLOOD CANCER DISCOVERY : Impact Factor & More
eISSN: 2643-3249pISSN: 2643-3230
Share this on:
Key Metrics
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on BLOOD CANCER DISCOVERY
BLOOD CANCER DISCOVERY Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
SJR
| Overview | |
| Publisher | AMER ASSOC CANCER RESEARCH |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 2020 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in BLOOD CANCER DISCOVERY ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in BLOOD CANCER DISCOVERY
LY3410738, a Covalent Inhibitor of Mutant IDH1/2, is Effective in Acute Myeloid Leukemia Preclinical Models.
- 23 Jul 2026
- Blood cancer discovery
The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem Cells.
- 21 Jul 2026
- Blood cancer discovery
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.
- 14 Jul 2026
- Blood cancer discovery
Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR-T Treated T-cell Lymphoid Malignancies.
- 8 Jul 2026
- Blood cancer discovery
MYST Acetyltransferases Interact with SETBP1 and Are a Targetable Therapeutic Vulnerability in SETBP1-Mutant Leukemia.
- 1 Jul 2026
- Blood cancer discovery
KATs in the MYST: A New Therapeutic Vulnerability for SETBP1-Mutated Myeloid Malignancies.
- 1 Jul 2026
- Blood cancer discovery
LY3410738, a Covalent Inhibitor of Mutant IDH1/2, is Effective in Acute Myeloid Leukemia Preclinical Models.
- 23 Jul 2026
- Blood cancer discovery
The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem Cells.
- 21 Jul 2026
- Blood cancer discovery
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.
- 14 Jul 2026
- Blood cancer discovery
Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR-T Treated T-cell Lymphoid Malignancies.
- 8 Jul 2026
- Blood cancer discovery
MYST Acetyltransferases Interact with SETBP1 and Are a Targetable Therapeutic Vulnerability in SETBP1-Mutant Leukemia.
- 1 Jul 2026
- Blood cancer discovery
KATs in the MYST: A New Therapeutic Vulnerability for SETBP1-Mutated Myeloid Malignancies.
- 1 Jul 2026
- Blood cancer discovery
FAQs on BLOOD CANCER DISCOVERY
How long has BLOOD CANCER DISCOVERY been actively publishing? 
What is the publishing frequency of BLOOD CANCER DISCOVERY?
How many articles did BLOOD CANCER DISCOVERY publish last year?
What is the eISSN & pISSN for BLOOD CANCER DISCOVERY?
Who is the publisher of BLOOD CANCER DISCOVERY?
